Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab
Friedlander P, Wassmann K, Christenfeld A, Fisher D, Kyi C, Kirkwood J, Bhardwaj N, Oh W. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. Journal For ImmunoTherapy Of Cancer 2017, 5: 67. PMID: 28807052, PMCID: PMC5557000, DOI: 10.1186/s40425-017-0272-z.Peer-Reviewed Original ResearchConceptsOne-year survivalArea under the curveMelanoma patientsCheckpoint inhibitorsClinical responseAnti-cancer immune responseMulticenter phase III studyBlocking CTLA-4Refractory melanoma patientsAdvanced melanoma patientsPhase II studyClinical studies of patientsPhase III studyBaseline prior to treatmentMethodsPeripheral blood samplesStudy of patientsUnmet clinical needRECIST criteriaAdvanced melanomaCTLA-4Immunotherapeutic interventionsIII studiesII studyTremelimumabClinical efficacy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply